Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection

被引:29
作者
Cai, XJ
Woo, MJ
Edick, MJ
Relling, MV [1 ]
机构
[1] Univ Tennessee, St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38101 USA
[2] Univ Tennessee, St Jude Childrens Res Hosp, Coll Pharm, Memphis, TN USA
来源
JOURNAL OF CHROMATOGRAPHY B | 1999年 / 728卷 / 02期
关键词
etoposide; etoposide catechol;
D O I
10.1016/S0378-4347(99)00110-3
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Etoposide, a highly active and widely used antineoplastic agent, is O-demethylated to its active catechol metabolite. A high-performance liquid chromatographic assay method for the simultaneous quantitation of etoposide and etoposide catechol in human plasma was established. Etoposide and etoposide catechol were extracted from plasma using chloroform and methanol followed by phase separation, evaporation of the organic phase, and reconstitution of the residue. Chromatography was accomplished using a reversed-phase phenyl analytical column (390 mmx3.9 mm I.D.) with a mobile phase of 76.6% 25 mM citric acid-50 mM sodium phosphate (pH 2.4)-23.4% acetonitrile pumped isocratically at 1 ml/min with electrochemical detection. The limit of detection for etoposide was 1.2 nM and for etoposide catechol was 0.2 nM. The precision (CV) for etoposide ranged from 0.7 to 3% and for the catechol metabolite from 1 to 6%; accuracy of predicted values ranged from 97 to 106% and 94 to 103%, respectively. The assay was linear from 0.1 to 10 mu M for etoposide and from 0.005 to 0.5 mu M for etoposide catechol in plasma. Recovery of etoposide and etoposide catechol ranged from 93 to 95% and 90 to 98%, respectively. Stability of etoposide and etoposide catechol in human plasma containing ascorbic acid stored at -70 degrees C for one year was demonstrated. This assay procedure is suitable for evaluation of etoposide and etoposide catechol pharmacokinetics in plasma following etoposide administration. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:241 / 250
页数:10
相关论文
共 21 条
[1]   THE CLINICAL-PHARMACOLOGY OF ETOPOSIDE AND TENIPOSIDE [J].
CLARK, PI ;
SLEVIN, ML .
CLINICAL PHARMACOKINETICS, 1987, 12 (04) :223-252
[2]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF ETOPOSIDE IN PLASMA USING ELECTROCHEMICAL DETECTION [J].
DUNCAN, GF ;
FARMEN, RH ;
MOVAHHED, HS ;
PITTMAN, KA .
JOURNAL OF CHROMATOGRAPHY, 1986, 380 (02) :357-365
[3]   The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II DNA cleavable complex [J].
Gantchev, TG ;
Hunting, DJ .
MOLECULAR PHARMACOLOGY, 1998, 53 (03) :422-428
[4]   Inhibition of the topoisomerase II DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16) [J].
Gantchev, TG ;
Hunting, DJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 237 (01) :24-27
[5]   INVITRO METABOLISM OF ETOPOSIDE (VP-16-213) BY LIVER-MICROSOMES AND IRREVERSIBLE BINDING OF REACTIVE INTERMEDIATES TO MICROSOMAL PROTEINS [J].
HAIM, N ;
NEMEC, J ;
ROMAN, J ;
SINHA, BK .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (04) :527-536
[6]  
HAIM N, 1987, CANCER RES, V47, P5835
[7]   CHARACTERIZATION OF FREE-RADICALS PRODUCED DURING OXIDATION OF ETOPOSIDE (VP-16) AND ITS CATECHOL AND QUINONE DERIVATIVES - AN ESR STUDY [J].
KALYANARAMAN, B ;
NEMEC, J ;
SINHA, BK .
BIOCHEMISTRY, 1989, 28 (11) :4839-4846
[8]  
LITTLEWOOD TJ, 1984, J CHROMATOGR, V36, P434
[9]   ROLE OF THE SEMIQUINONE FREE-RADICAL OF THE ANTITUMOR AGENT ETOPOSIDE (VP-16-213) IN THE INACTIVATION OF SINGLE-STRANDED AND DOUBLE-STRANDED PHI-X174 DNA [J].
MANS, DRA ;
RETEL, J ;
VANMAANEN, JMS ;
LAFLEUR, MVM ;
VANSCHAIK, MA ;
PINEDO, HM ;
LANKELMA, J .
BRITISH JOURNAL OF CANCER, 1990, 62 (01) :54-60
[10]  
RELLING MV, 1992, J PHARMACOL EXP THER, V261, P491